The mechanism of the opening of the blood-brain barrier by borneol: a pharmacodynamics and pharmacokinetics combination study.

ETHNOPHARMACOLOGICAL RELEVANCE Borneol is widely used in traditional Chinese medicine to facilitate the distribution of central nervous system (CNS) drugs in brain due to its ability to open blood-brain barrier (BBB), however, the underlying mechanism is still unclear. In this study, the effect of borneol on different brain regions were investigated to explore the mechanism. MATERIALS AND METHODS After oral administration of borneol (0.1, 0.2 g/kg) for seven consecutive days, SD rats were injected with Rh123 (1.0 mg/kg). The concentrations of Rh123 were detected in four brain regions of cortex, hippocampus, hypothalamus and striatum by a small animal vivo imaging system and a fluorescence microplate reader respectively. The ultrastructures of BBB were examined. Moreover, the expressions of the four transporters of ATP-binding cassette (ABC) family, multidrug resistance 1a (Mdr1a), multidrug resistance 1b (Mdr1b), multidrug resistance protein 1 (Mrp1), Mrp4, Mrp5 and breast cancer resistance protein (Bcrp) in the four brain regions were analyzed. Finally, the deliveries of borneol in the plasma and the four brain regions were examined by a pharmacokinetics study. RESULTS Administration of 0.2 g/kg borneol produced loose structure in the tight junction and void structure between the endothelial cell and mesangial cell. Borneol at 0.1 g/kg and 0.2 g/kg increased the delivery of Rh123 in hippocampus and hypothalamus obviously. Permeability index followed a similar trend. Protein expression assays showed that borneol decreased the expression of Mdr1 and Mrp1 in hippocampus and hypothalamus. Further RT-PCR study showed that borneol decreased the expressions of both Mdr1a and Mdr1b in hippocampus and hypothalamus. The pharmacokinetics study demonstrated that the delivery of borneol in cortex was the most and that in striatum the least, with the deliveries of borneol in hippocampus and hypothalamus in between. CONCLUSIONS Borneol showed tissue specific BBB-opening effect, which was associated with its regulation of the ultrastructure of brain tissues and the expressions of Mdr1a, Mdr1b and Mrp1. The present study indicated that borneol should be used in concert with drugs targeting hippocampus or hypothalamus to exert its synergistic effect to the maximum.

[1]  A. Misra,et al.  Drug delivery to the central nervous system: a review. , 2003, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[2]  Yanwei Xing,et al.  Baicalin reduces the permeability of the blood-brain barrier during hypoxia in vitro by increasing the expression of tight junction proteins in brain microvascular endothelial cells. , 2012, Journal of ethnopharmacology.

[3]  R. Béliveau,et al.  P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. , 1997, The Biochemical journal.

[4]  Shixiang Hou,et al.  Effect of borneol on the distribution of gastrodin to the brain in mice via oral administration , 2008, Journal of drug targeting.

[5]  Yong-qiu Zheng,et al.  [Effect and mechanism of huatuo zaizao extractum on focal cerebral ischemia/reperfusion-induced blood-brain barrier injury in rats]. , 2013, Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica.

[6]  H. Galla,et al.  Regulation of major efflux transporters under inflammatory conditions at the blood‐brain barrier in vitro , 2009, Journal of neurochemistry.

[7]  Lars Bäckman,et al.  Transfer of Learning After Updating Training Mediated by the Striatum , 2008, Science.

[8]  J. Flier,et al.  Neurogenesis in the Hypothalamus of Adult Mice: Potential Role in Energy Balance , 2005, Science.

[9]  R. Kim,et al.  Blood−brain barrier transporters and response to CNS-active drugs , 2009, European Journal of Clinical Pharmacology.

[10]  Xiao-rong Li,et al.  Pharmacokinetic interaction between puerarin and edaravone, and effect of borneol on the brain distribution kinetics of puerarin in rats , 2010, The Journal of pharmacy and pharmacology.

[11]  P. L. Golden,et al.  Blood-brain barrier efflux transport. , 2003, Journal of pharmaceutical sciences.

[12]  D. Shohamy,et al.  Preference by Association: How Memory Mechanisms in the Hippocampus Bias Decisions , 2012, Science.

[13]  B. Roques,et al.  Cytoskeletal Genes Regulation by Chronic Morphine Treatment in Rat Striatum , 2004, Neuropsychopharmacology.

[14]  C. Rousselle,et al.  Apparent Lack of Mrp1-Mediated Efflux at the Luminal Side of Mouse Blood-Brain Barrier Endothelial Cells , 2003, Pharmaceutical Research.

[15]  M. Ruan,et al.  Effects of borneol on the pharmacokinetics of geniposide in cortex, hippocampus, hypothalamus and striatum of conscious rat by simultaneous brain microdialysis coupled with UPLC-MS. , 2013, Journal of pharmaceutical and biomedical analysis.

[16]  E. Melamed,et al.  Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier , 2001, Neuropharmacology.

[17]  R. Pi,et al.  The orally combined neuroprotective effects of sodium ferulate and borneol against transient global ischaemia in C57 BL/6J mice. , 2010, The Journal of pharmacy and pharmacology.

[18]  Ling He,et al.  In Vitro and In Vivo Study of CJY, an Isoflavone, on P-Glycoprotein Function in Rats , 2008, Journal of chemotherapy.

[19]  H. Kusuhara,et al.  Involvement of multidrug resistance associated protein 1 (Mrp1) in the efflux transport of 17beta estradiol-D-17beta-glucuronide (E217betaG) across the blood-brain barrier. , 2003, Pharmaceutical research.

[20]  David J. Begley,et al.  Structure and function of the blood–brain barrier , 2010, Neurobiology of Disease.

[21]  W. Pardridge,et al.  Delivery of β-Galactosidase to Mouse Brain via the Blood-Brain Barrier Transferrin Receptor , 2005, Journal of Pharmacology and Experimental Therapeutics.

[22]  M. Barrand,et al.  Localisation of breast cancer resistance protein in microvessel endothelium of human brain , 2002, Neuroreport.

[23]  W. Pardridge The blood-brain barrier: Bottleneck in brain drug development , 2005, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.

[24]  P. Nava,et al.  Tight junction proteins. , 2003, Progress in biophysics and molecular biology.

[25]  Soojin Lee,et al.  Neuroprotective effect of SuHeXiang Wan in Drosophila models of Alzheimer's disease. , 2011, Journal of ethnopharmacology.

[26]  Sagar Agarwal,et al.  Saturable Active Efflux by P-Glycoprotein and Breast Cancer Resistance Protein at the Blood-Brain Barrier Leads to Nonlinear Distribution of Elacridar to the Central Nervous System , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[27]  Jian rong Liu,et al.  The protective role of Tongxinluo on blood-brain barrier after ischemia-reperfusion brain injury. , 2013, Journal of ethnopharmacology.

[28]  Caiyun Wang,et al.  Expressions of apoptosis-related proteins in rats with focal cerebral ischemia after Angong Niuhuang sticker point application☆ , 2012, Neural Regeneration Research.

[29]  P. Wielinga,et al.  Mrp4 Confers Resistance to Topotecan and Protects the Brain from Chemotherapy , 2004, Molecular and Cellular Biology.

[30]  M. Shapiro,et al.  Reward Stability Determines the Contribution of Orbitofrontal Cortex to Adaptive Behavior , 2012, The Journal of Neuroscience.

[31]  N. Cholet,et al.  Role of P‐170 glycoprotein in colchicine brain uptake , 1997, Journal of neuroscience research.